BIIB

BiogenB

Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences

At close

2026-06-02

View Chart

AI scenario view

RankAlpha Sentiment Codex

B+

Bull case

Probability

Target price

$220.00

+16.5% vs current

Most likely

Base case

Probability

Target price

$203.00

+7.5% vs current

B-

Bear case

Probability

Target price

$170.00

-10.0% vs current

AI sentiment snapshot

Latest data as of 2026-04-29

AI commentary

Post-earnings tone is mixed and should remain a monitoring view. Recent headlines emphasized both the Q1 beat and the lowered 2026 earnings outlook, while trusted coverage described an initially positive share reaction. That supports a tentative improvement in tone, but analyst revision coverage is unavailable at this T+1 stage and the 2026 guidance reset, Apellis financing, and legacy-product pressure keep forward evidence limited.

RankAlpha Sentiment Codex - 2026-04-29

Open full AI memo

Evidence flagged

memo remains a monitoring view with limited forward evidence and should not be standard-conviction

Impact

tentative

Confidence

AI events

2026-05-06catalystQ1 beat offsets part of the guidance cut in near-term tape digestionMedium impact

Biogen reported Q1 2026 revenue of $2.478 billion and non-GAAP EPS of $3.57, while updating 2026 non-GAAP EPS guidance to $14.25-$15.25 from $15.25-$16.25 because of roughly $1.00 of acquired IPR&D charges tied to business-development activity; trusted coverage described an initially positive share reaction despite the reduced earnings outlook. [#8-K-2026-04-29]

2026-05-24eventLEQEMBI subcutaneous autoinjector FDA decision on May 24, 2026Medium impact

The 10-Q says the FDA accepted the supplemental BLA for LEQEMBI IQLIK with a May 24, 2026 PDUFA date, creating a dated regulatory catalyst for Alzheimer’s franchise convenience and uptake. [#10-Q-2026-04-29]

2027-04-29catalystApellis close and nephrology buildout could reshape the 2026-2027 growth mixMedium impact

Biogen expects the Apellis acquisition to close in Q2 2026, fund it with about $3.6 billion of cash/marketable securities plus about $2.0 billion of bank loans, and later provide updated 2026 guidance inclusive of Apellis; the company also acquired Greater China rights to felzartamab, reinforcing the nephrology strategy. [#8-K-2026-04-29] [#10-Q-2026-04-29]

View full catalyst timeline

Recommendation

N/A

No formal recommendation provided.

Open AI Memo

As of 2026-04-29 • Updated nightlySource: Internal modelMethodology